Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00839956 · OUTCOME

Time to Disease Progression in Patients Who Progressed

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant · Source last updated 2017-05-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
years
Interval / dispersion
Full Range
Time frame
Up to 5 years

What was measured

Patients will be followed for initial response to therapy and for progression of disease. Response criteria will be scored according to International Myeloma Working Group uniform response criteria.

Analysis population: One subject withdrew from the study within first week of study therapy and changed to different therapy and is not included in this outcome measure.

Groups in this outcome

Arm I (Bortezomib and Vorinostat)

Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Bortezomib: Given IV Vorinostat: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Bortezomib and Vorinostat)30

Reported measurements

Source class 1
Values in years · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Arm I (Bortezomib and Vorinostat)2.1Not reported0.335.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.33
        upper Limit
        5.3
        value
        2.1
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
Patients will be followed for initial response to therapy and for progression of disease. Response criteria will be scored according to International Myeloma Working Group uniform response criteria.
dispersion Type
Full Range
groups
  1. description
    Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Bortezomib: Given IV Vorinostat: Given PO
    id
    OG000
    title
    Arm I (Bortezomib and Vorinostat)
param Type
MEDIAN
population Description
One subject withdrew from the study within first week of study therapy and changed to different therapy and is not included in this outcome measure.
reporting Status
POSTED
time Frame
Up to 5 years
title
Time to Disease Progression in Patients Who Progressed
type
SECONDARY
unit Of Measure
years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice